“ORDERED, ADJUDGED AND DECREED as follows: 1. This District Court has jurisdiction over the subject matter of the above action and has personal jurisdiction over the parties. 2. As used in this Consent Judgment, Mylan mean the drug product sold, offered for sale or distributed pursuant to Abbreviated New Drug Application No. 211161 (including any supplements or amendments thereto or replacements Mylan ANDA No. 211161 ii) States Patent Number 7,094,781 that, directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with Mylan; f (a) ownership, directly or through one or more intermediaries, of (1) more than fifty percent (50%) of the shares of stock entitled to vote for the election of directors, in the case of a corporation, or (2) more than fifty percent (50%) of the equity interests in the case of any other type of legal entity or status as a general partner in any partnership, or (b) any other arrangement whereby an entity or person has the right to elect a majority of the Board of Directors or equivalent governing body of a corporation or other entity or the right to direct the management and policies of a corporation or other entity. 3. Solely for the purposes of settling the Action, Mylan admits that the claims of the Licensed Patent are valid and enforceable, and that the claims of the Licensed Case 1:23-cv-00088-TSK Document 35 Filed 09/20/24 Page 2 of 4 PageID #: 283 – 3 – Patent would be infringed by the commercial manufacture, use, sale, offer for sale, or importation of the Mylan Product in the United States prior to expiration of the Licensed Patent. 4. Unless otherwise specifically authorized by Actelion, Mylan, including any of its Affiliates, successors and assigns, is enjoined from infringing the Licensed Patent, on its own part or through any Affiliate, by making, having made, using, selling, offering to sell, importing or distributing the Mylan Product in the United States. 5. This District Court retains jurisdiction to enforce or supervise performance under this Consent Judgment. 6. All claims, counterclaims, affirmative defenses and demands in this action party. 7. Nothing herein shall prohibit or restrict Mylan from maintaining or filing paragraph IV certifications in M 211161 under 21 U.S.C. § 355(j)(2)(A)(vii)(IV) (as amended or supplemented) and nothing herein shall prohibit or restrict at any time. Each party acknowledges and agrees that the 30- ANDA No. 211161 under 21 U.S.C. § 355(j)(5)(B)(iii) is hereby terminated.”